The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
- 1 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21), 5747-5758
- https://doi.org/10.1158/1078-0432.ccr-20-1315
Abstract
Purpose: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells. In this study, we evaluated if KPT-8602 would synergize with dexamethasone, vincristine or doxorubicin, three drugs currently used for the treatment of ALL. Experimental design: First, we searched for the most synergistic combination of KPT-8602 with dexamethasone, vincristine or doxorubicin in vitro in both B-ALL and T-ALL cell lines using proliferation and apoptosis as a readout. Next, we validated this synergistic effect by treatment of clinically relevant B- and T-ALL patient derived xenograft models (PDX) in vivo. Finally, we performed RNA-sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) to determine the mechanism of synergy. Results: KPT-8602 showed strong synergism with dexamethasone on human B-ALL and T-ALL cell lines as well as in vivo in three patient-derived ALL xenografts. Compared to single drug treatment, the drug combination caused increased apoptosis and led to histone depletion. Mechanistically, integration of ChIP-seq and RNA-seq data revealed that addition of KPT-8602 to dexamethasone enhanced the activity of the glucocorticoid receptor (NR3C1) and led to increased inhibition of E2F mediated transcription. We observed strong inhibition of E2F target genes related to cell cycle, DNA replication and transcriptional regulation. Conclusion: Our pre-clinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1 and E2F mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.Other Versions
Funding Information
- KU Leuven (C14/18/104)
This publication has 56 references indexed in Scilit:
- The molecular basis of T cell acute lymphoblastic leukemiaJCI Insight, 2012
- The Hypersensitive Glucocorticoid Response Specifically Regulates Period 1 and Expression of Circadian GenesMolecular and Cellular Biology, 2012
- i-cisTarget: an integrative genomics method for the prediction of regulatory features and cis-regulatory modulesNucleic Acids Research, 2012
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012
- Research Resource: Transcriptional Response to Glucocorticoids in Childhood Acute Lymphoblastic LeukemiaMolecular Endocrinology, 2012
- Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemiaBMC Genomics, 2011
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- Cajal body surveillance of U snRNA export complex assemblyThe Journal of cell biology, 2010
- Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulationGenome Research, 2009
- GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signalingJCI Insight, 2007